NurExone Biologic’s $2M Capital Raise Advances Therapy Development

EnerSpar Corp. (TSE:NRX) has released an update.

NurExone Biologic Inc., a biopharmaceutical company focused on regenerative medicine, has announced a non-brokered private placement aiming to raise up to $2 million, with the first tranche already closed at $1.61 million. The funds are intended for working capital to help the company advance its exosome-based therapies for spinal cord injuries and optic nerve damage. Shareholders have shown confidence in the company’s strategic direction by participating in the offering, reflecting their belief in its long-term growth potential.

For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.